Previous 10 | Next 10 |
Trovagene (NASDAQ: TROV ) has initiated patient enrollment in its Phase 1b/2 study of onvansertib in combination with FOLFIRI and Avastin (bevacizumab) for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation. More news on: TrovaGene, Inc...
SAN DIEGO , July 9, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company, today announced the initiation of patient enrollment of its Phase 1b /2 study of onvansertib in combination with FO...
SAN DIEGO , May 30, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, a...
Netshoes (NYSE: NETS ) +36% on takeover offer report. More news on: Netshoes (Cayman) Limited, Avon Products, Inc., Tonix Pharmaceuticals Holding Corp., Stocks on the move, Read more ...
Nano cap Trovagene (NASDAQ: TROV ) perks up 5% premarket on light volume in reaction to its research collaboration with Nektar Therapeutics (NASDAQ: NKTR ) to explore the combination of TROV's onvansertib and NKTR's ONZEALD (etirinotecan pegol) in tumor models of colorecta...
SAN DIEGO , May 23, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, a...
Trovagene (NASDAQ: TROV ) has entered into a second purchase agreement with Lincoln Park Capital Fund, LLC, in which Lincoln Park has agreed to purchase at premium, in a registered direct offering 196,104 common shares at $3.275 per share and pre-funded warrants at $3.275 per warrant. Mo...
SAN DIEGO , May 13, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, an...
Trovagene (NASDAQ: TROV ): Q1 GAAP EPS of -$1.02 beats by $0.05 . More news on: TrovaGene, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO , May 7, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, ...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...